Jul 25, 2025Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jun 17, 2025Lilley to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
May 14, 2025Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
Apr 14, 2025Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Apr 11, 2025Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9